BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34305925)

  • 1. Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis.
    Won P; Kim Y; Jung H; Rim YA; Sohn DH; Robinson WH; Moon SJ; Ju JH
    Front Immunol; 2021; 12():692242. PubMed ID: 34305925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis.
    Kawaguchi H; Matsumoto I; Osada A; Kurata I; Ebe H; Tanaka Y; Inoue A; Umeda N; Kondo Y; Tsuboi H; Shinkai Y; Kumagai Y; Ishigami A; Sumida T
    Arthritis Res Ther; 2018 Apr; 20(1):66. PubMed ID: 29636082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis.
    Shoda H; Fujio K; Shibuya M; Okamura T; Sumitomo S; Okamoto A; Sawada T; Yamamoto K
    Arthritis Res Ther; 2011; 13(6):R191. PubMed ID: 22108001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis.
    Titcombe PJ; Wigerblad G; Sippl N; Zhang N; Shmagel AK; Sahlström P; Zhang Y; Barsness LO; Ghodke-Puranik Y; Baharpoor A; Hansson M; Israelsson L; Skriner K; Niewold TB; Klareskog L; Svensson CI; Amara K; Malmström V; Mueller DL
    Arthritis Rheumatol; 2018 Dec; 70(12):1933-1945. PubMed ID: 29927106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis.
    Goules JD; Goules AV; Tzioufas AG
    Clin Exp Immunol; 2013 Oct; 174(1):10-7. PubMed ID: 23711220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti -citrullinated peptide antibodies profiling in established rheumatoid arthritis.
    Manca ML; Alunno A; D'Amato C; Bistoni O; Puxeddu I; Gerli R; Migliorini P; Pratesi F
    Joint Bone Spine; 2018 Jul; 85(4):441-445. PubMed ID: 28826660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis.
    Sieghart D; Platzer A; Studenic P; Alasti F; Grundhuber M; Swiniarski S; Horn T; Haslacher H; Blüml S; Smolen J; Steiner G
    Front Immunol; 2018; 9():876. PubMed ID: 29740454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.
    Vittecoq O; Incaurgarat B; Jouen-Beades F; Legoedec J; Letourneur O; Rolland D; Gervasi G; Ménard JF; Gayet A; Fardellone P; Daragon A; Jolivet M; le Loët X; Tron F
    Clin Exp Immunol; 2004 Jan; 135(1):173-80. PubMed ID: 14678280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis.
    Liang B; Ge C; Lönnblom E; Lin X; Feng H; Xiao L; Bai J; Ayoglu B; Nilsson P; Nandakumar KS; Zhao M; Holmdahl R
    Rheumatology (Oxford); 2019 Sep; 58(9):1623-1633. PubMed ID: 30892636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.
    Schwenzer A; Jiang X; Mikuls TR; Payne JB; Sayles HR; Quirke AM; Kessler BM; Fischer R; Venables PJ; Lundberg K; Midwood KS
    Ann Rheum Dis; 2016 Oct; 75(10):1876-83. PubMed ID: 26659718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [No Abstract]   [Full Text] [Related]  

  • 15. Independence of carbohydrate-deficient isoforms of transferrin and cyclic citrullinated peptides in rheumatoid arthritis.
    Gudowska M; Gindzienska-Sieskiewicz E; Gruszewska E; Cylwik B; Sierakowski S; Szmitkowski M; Chrostek L
    Rev Bras Reumatol Engl Ed; 2017; 57(3):185-189. PubMed ID: 28535888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the ability of anti-cyclic citrullinated peptide antibodies determination in synovial fluid in discriminating rheumatoid arthritis from non-rheumatoid arthritis patients? A Tunisian cross-sectional study.
    Mrabet D; Laadhar L; Sahli H; Zouari B; Haouet S; Lahmar H; Makni S; Sellami S
    Clin Rheumatol; 2012 Feb; 31(2):375-9. PubMed ID: 21952975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of synthetic manufactured peptides containing common citrullinated epitopes in rheumatoid arthritis diagnosis.
    Darawshe S; Watad A; Bragazzi NL; Gertel S; Amital H
    Clin Immunol; 2019 Feb; 199():7-11. PubMed ID: 30543920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
    Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
    Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.